Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

With its innovative features and the upcoming launch of a direct medication purchasing service, Gala is set to become the ...

We all react to environmental cues that tell us it’s time to eat, like the scent of fries wafting through the air. These cues ...

(Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) For those who are overweight or obese, medications known as glucagon-like peptide-1 agonists, or GLP-1s, have become very ...

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

Between Novo Nordisk's (NVO) slightly disappointing results for its latest GLP-1 candidate, CagriSema, and questions that remain about Amgen's (AMGN) highly anticipated once-monthly injectable ...